2 unknown, 1 not yet recruiting, 1 recruiting. 4 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Unknown 2, Not yet recruiting 1, Recruiting 1 |
Follow Neoadjuvant Therapy: new trials by email Literature Review of Neoadjuvant Therapy trials Research Report on Neoadjuvant Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer olaparib combined with trastuzumab and pertuzumab - Elderly Females, HER2 + Breast Cancer | Phase 4 | Recruiting | Wen-Ming Cao | 45 | 2026-05-25 | 2026-07-10 |
| Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study Ensartinib - ALK-positive Advanced NSCLC, ALK-positive Non-small Cell Lung Cancer (NSCLC) | Phase 4 | Not yet recruiting | Fujian Medical University Union Hospital | 30 | 2025-02-01 | 2025-01-21 |
| The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression Disitamab Vedotin combined with Tislelizumab - Breast Cancer, Neoadjuvant Therapy | Phase 4 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 42 | 2023-02-01 | 2023-05-17 |
| Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer S-1, 5-FU - Breast Neoplasms, Neoadjuvant Therapy | Phase 4 | Unknown | Shandong University | 240 | 2013-06-01 | 2013-05-08 |
Breast Neoplasms (3)
Breast Diseases (3) · Neoplasms (3) · Neoplasms by Site (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3)
Fluorouracil (1) · S 1 (combination) (1) · Trastuzumab (1) · ensartinib (1) · pertuzumab (1) · tislelizumab (1)
Fujian Medical University Union Hospital (1) · Shandong University (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · Wen-Ming Cao (1)
China (4)
Gang Z Yu, Dr; PhD (1) · Jing Yao (1)